Active Ingredient History
Argatroban is a synthetic direct thrombin inhibitor derived from L-arginine. Argatroban is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Argatroban does not require the co-factor antithrombin III for antithrombotic activity. Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation. Argatroban is highly selective for thrombin with an inhibitory constant (Ki) of 0.04 µM. At therapeutic concentrations, Argatroban has little or no effect on related serine proteases (trypsin, factor Xa, plasmin, and kallikrein). Argatroban is capable of inhibiting the action of both free and clot-associated thrombin. Argatroban is indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia. Argatroban is indicated as an anticoagulant in patients with or at risk for heparin-induced thrombocytopenia undergoing percutaneous coronary intervention (PCI). NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Thrombosis (approved 2000)
Angina, Unstable (Phase 2)
Anticoagulants (Phase 2/Phase 3)
Blood Platelets (Phase 4)
Brain Ischemia (Phase 2)
Coronary Artery Disease (Phase 2)
COVID-19 (Phase 4)
Drugs, Investigational (Phase 4)
Extracorporeal Membrane Oxygenation (Phase 2/Phase 3)
General Surgery (Phase 4)
Genital Neoplasms, Female (Phase 3)
Heart Diseases (Phase 4)
Heparin, Low-Molecular-Weight (Phase 3)
Ischemic Stroke (Phase 4)
Kidney Failure, Chronic (Phase 4)
Staphylococcal Infections (Phase 2)
Stroke (Phase 4)
Thrombosis (Phase 4)
Venous Thromboembolism (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue